GDNF Gene Therapy for Parkinson's Disease

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

April 1, 2020

Primary Completion Date

October 17, 2023

Study Completion Date

June 30, 2027

Conditions
Parkinson's Disease
Interventions
BIOLOGICAL

AAV2-GDNF

Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Trial Locations (3)

43210

The Ohio State University Medical Center, Columbus

92697

University of California Irvine, Irvine

94103

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AskBio Inc

INDUSTRY

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Brain Neurotherapy Bio, Inc.

INDUSTRY

NCT04167540 - GDNF Gene Therapy for Parkinson's Disease | Biotech Hunter | Biotech Hunter